Ombretta Annibali

22PUBLICATIONS
166CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMajor global burdens of diseaseAutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 18, 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

|Jun 18, 2026
Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

|May 27, 2026
Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

|May 09, 2026
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

|Jan 14, 2026
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient Journey.

Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali

|Sep 08, 2025
Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.

Tiziana Bruno, Maria Chiara Cappelletto, Clelia Cortile

Pageof 4

Frequent Collaborators

3 joint publications

Francesco Pisani

3 joint publications

Stefano Luminari

2 joint publications

Francesca Fazio

2 joint publications

Gregorio Barilà